

Selective Laser Trabeculoplasty for Primary Angle-Closure Glaucoma: a pilot case study

Submission date 05/05/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 03/07/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 11/08/2008	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Michael Belkin

Contact details
Goldschleger Eye Research Institute
Tel Aviv University
Sheba Medical Center
Tel Hashomer
Israel
52621

Additional identifiers

Study information

Scientific Title

Acronym
SLT for PACG Study

Study objectives

To determine whether selective laser trabeculoplasty (SLT) using a Q-switched frequency doubled neodymium-doped yttrium aluminium garnet (Nd:YAG) laser is effective in lowering intraocular pressure in patients with primary angle-closure glaucoma (PACG).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from:

1. Singapore Eye Research Institute (SERI-Singapore) (Ref: R424/19/2005) dated 27/10/2005
2. United Christian Hospital (Hong Kong) (Ref: KC/KE05-0073/FR-3) dated on 15/06/2005

Other ethics approval from Chulalongkorn University and Hospital (Thailand), St. Luke's Medical Centre (Philippines) and National University Hospital (Singapore).

Study design

Prospective, observational, uncontrolled, non-comparative study

Primary study design

Observational

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Primary angle-closure glaucoma

Interventions

Selective laser trabeculoplasty (SLT)

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

Intraocular pressure (IOP) at regular intervals of follow-up with the final IOP being measured at six months after the last treatment. Successful outcome defined as greater or equal to 20% reduction in IOP from pre-laser levels.

Key secondary outcome(s)

IOP measured on other eye if both eyes are eligible for the study.

Completion date

01/07/2006

Eligibility

Key inclusion criteria

1. PACG
2. Intraocular pressure 21 - 28 mmHg on one or more topical medicine in presence of patent iridotomy
3. At least two months since last iridotomy
4. Aged over 21 years old

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Secondary causes of angle-closure
2. Corneal abnormalities
3. Advanced glaucomatous optic neuropathy
4. Patient blind in one eye

Date of first enrolment

01/07/2005

Date of final enrolment

01/07/2006

Locations**Countries of recruitment**

Hong Kong

Israel

Philippines

Singapore

Thailand

Study participating centre

Goldschleger Eye Research Institute

Tel Hashomer

Israel

52621

Sponsor information

Organisation

Ellex Medical Pty. Ltd. (Australia)

Funder(s)

Funder type

Industry

Funder Name

Ellex Medical Pty Ltd (Australia)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration